EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. Guillermo, Jänne, Pasi A., Lee, Jeffrey C., Tracy, Sean, Greulich, Heidi, Gabriel, Stacey, Herman, Paula, Kaye, Frederic J. +9 more·2004·Science
DOI 10.1126/science.1099314

Cited by (1,066)

Items 401–500 of 1,066

  1. Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
    Yibing Shan, Michael P. Eastwood, Xuewu Zhang, Eric T. Kim, Anton S. Arkhipov, Ron O. Dror, John Jumper, John Kuriyan, David Elliot Shaw · 2012 · Cell
  2. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
    Neil L. Spector, Wenle Xia, Howard A. Burris, Herbert I. Hurwitz, E. Claire Dees, Afshin Dowlati, Bert H. O’Neil, Beth A. Overmoyer, Paul Kelly Marcom, Kimberly Blackwell et al. · 2005 · Journal of Clinical Oncology
  3. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
    Roman Kurt Thomas, Elizabeth Nickerson, Jan Fredrik Simons, Pasi Antero Janne, Torstein Tengs, Yuki Yuza, Levi A. Garraway, Thomas LaFramboise, Jeffrey C. Lee, Kinjal Shah et al. · 2006 · Nature Medicine
  4. Molecular Genetics of Acute Lymphoblastic Leukemia
    Scott A. Armstrong, Alfred Thomas Look · 2005 · Journal of Clinical Oncology
  5. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
    Gregory J. Riely, Katerina A. Politi, Vincent A. Miller, William J. Pao · 2006 · Clinical Cancer Research
  6. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
    Federico Cappuzzo, Elisabetta Magrini, Giovanni Luca Ceresoli, Stefania Bartolini, Elisa Rossi, V. Ludovini, Vanesa Gregorc, C. Ligorio, Alessandra Cancellieri, Stefania Damiani et al. · 2004 · JNCI Journal of the National Cancer Institute
  7. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Jessica J. Lin, Stephanie Cardarella, Christine Lydon, Suzanne Eleanor Dahlberg, David Michael Jackman, Pasi Antero Janne, Bruce Evan Johnson · 2015 · Journal of Thoracic Oncology
  8. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
    Rohit Bhargava, William L. Gerald, Allan R. Li, Qiulu Pan, Priti Lal, Marc Ladanyi, Beiyun Chen · 2005 · Modern Pathology
  9. Cancer associated fibroblasts: An essential role in the tumor microenvironment
    Tao, Leilei, Huang, Guichun, Song, Haizhu, Chen, Yitian, Chen, Longbang · 2017 · Oncology Letters
  10. Expression Profile–Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors
    Toshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, Takayuki Kosaka, Hirotaka Osada, Kiyoshi Yanagisawa, Tetsuya Mitsudomi, Takashi Takahashi · 2006 · Journal of Clinical Oncology
  11. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression
    Xiangming Ji, Jun Qian, S.M. Jamshedur Rahman, Peter J. Siska, Yong Zou, Bradford K. Harris, Megan D. Hoeksema, Irina A. Trenary, Heidi Chen, Rosana Eisenberg et al. · 2018 · Oncogene
  12. Lineage dependency and lineage-survival oncogenes in human cancer
    Levi A. Garraway, William R. Sellers · 2006 · Nature reviews. Cancer
  13. Gold nanoparticles: From nanomedicine to nanosensing
    Adegboyega K. Oyelere · 2008 · Nanotechnology Science and Applications
  14. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
    Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner et al. · 2019 · Cancer Discovery
  15. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., Lassman, A. B. · 2011 · Neuro-Oncology
  16. Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Justin F. Gainor, Alice Tsang Shaw · 2013 · Journal of Clinical Oncology
  17. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
    Xiuning Le, Monique B. Nilsson, Jonathan Wade Goldman, Martin Reck, Kazuhiko Nakagawa, T. Kato, Luis Paz Ares, Bente Frimodt‐Moller, Katharina Wolff, Carla Visseren‐Grul et al. · 2020 · Journal of Thoracic Oncology
  18. Gene Copy-Number Alterations: A Cost-Benefit Analysis
    Tang, Yun-Chi, Amon, Angelika · 2013 · Cell
  19. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
    George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu et al. · 2009 · Clinical Cancer Research
  20. Central Nervous System Tumors
    Jan C. Buckner, Paul D. Brown, Brian Patrick O’Neill, Fredric Bruce Meyer, Cynthia Wetmore, Joon H. Uhm · 2007 · Mayo Clinic Proceedings
  21. Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
    Pablo Perez-Moreno, Elisabeth M. Brambilla, Roman Kurt Thomas, Jean‐Charles Soria · 2012 · Clinical Cancer Research
  22. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
    Justin F. Gainor, Alice Tsang Shaw · 2013 · The Oncologist
  23. Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
    Igor Vivanco, H. Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes, Phioanh Leia Nghiemphu, Sara Kubek, Barbara Oldrini, Milan G. Chheda, Nicolas A. Yannuzzi et al. · 2012 · Cancer Discovery
  24. Rational design of shepherdin, a novel anticancer agent
    Janet Plescia, Whitney Salz, Fang Xia, Marzia Pennati, Nadia Zaffaroni, Maria Grazia Daidone, Massimiliano Meli, Takehiko Dohi, Paola Fortugno, Yulia Nefedova et al. · 2005 · Cancer Cell
  25. Drug-sensitive FGFR2 mutations in endometrial carcinoma
    Amit Dutt, Helga Birgitte Salvesen, Tzu-Hsiu Chen, Alex H. Ramos, Robert C. Onofrio, Charlie Hatton, Richard Nicoletti, Wendy Winckler, Rupinder Grewal, Megan Hanna et al. · 2008 · Proceedings of the National Academy of Sciences
  26. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
    Gabriele Schaefer, Lauric Haber, Lisa Crocker, Steven Shia, Lily Shao, Donald J. Dowbenko, Klára Tótpál, Anne Wong, Chingwei V. Lee, Scott S. Stawicki et al. · 2011 · Cancer Cell
  27. Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
    Mark Steven Cragg, Junya Kuroda, Hamsa Puthalakath, David C.S. Huang, Andreas Strasser · 2007 · PLoS Medicine
  28. Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Helena Alexandra Yu, Camelia S. Sima, James Guoxian Huang, Stephen Barnett Solomon, Andreas Rimner, Paul K. Paik, Maria Catherine Pietanza, Christopher G. Azzoli, Naiyer A. Rizvi, Lee M. Krug et al. · 2013 · Journal of Thoracic Oncology
  29. Big Data and machine learning in radiation oncology: State of the art and future prospects
    Bibault, Jean-Emmanuel, Giraud, Philippe, Burgun, Anita · 2016 · Cancer Letters
  30. The epidermal growth factor receptor: from development to tumorigenesis
    Maria Chiara Sibilia, Renate Kroismayr, Beate M. Lichtenberger, Anuradha Natarajan, Manfred Hecking, Martin Holcmann · 2007 · Differentiation
  31. The future of epigenetic therapy in solid tumours—lessons from the past
    Nilofer Saba Azad, Cynthia A. Zahnow, Charles M. Rudin, Stephen B. Baylin · 2013 · Nature Reviews Clinical Oncology
  32. Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
    Floriana Morgillo, Jong Kyu Woo, Edward S. Kim, Waun Ki Hong, Ho‐Young Lee · 2006 · Cancer Research
  33. Disrupting insulin-like growth factor signaling as a potential cancer therapy
    Deepali Sachdev, Douglas Yee · 2007 · Molecular Cancer Therapeutics
  34. Making sense of cancer genomic data
    Lynda Chin, William C. Hahn, Gad A. Getz, Matthew M. Meyerson · 2011 · Genes & Development
  35. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
    Yihua Sun, Yan Ren, Zhaoyuan Fang, Chenguang Li, Rong Fang, Bin Gao, Xiangkun Han, Weidong Tian, William J. Pao, Haiquan Chen et al. · 2010 · Journal of Clinical Oncology
  36. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
    Yuankai Shi, Lingjian Wang, Baohui Han, WenShao Li, P. Yu, Y.P. Liu, C.M. Ding, Xia Song, Z.Y. Ma, X.L. Ren et al. · 2017 · Annals of Oncology
  37. Strategies to overcome resistance to targeted protein kinase inhibitors
    Henrik Daub, Katja Specht, Axel Ullrich · 2004 · Nature Reviews Drug Discovery
  38. RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer
    Gerold Bepler, Irina Kusmartseva, Swati Sharma, Ashish Gautam, Alan B Cantor, Anupama Sharma, George R. Simon · 2006 · Journal of Clinical Oncology
  39. Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis
    Xiaojun Zhao, Barbara A. Weir, Thomas LaFramboise, Ming Gang Lin, Rameen Beroukhim, Levi A. Garraway, Javad Beheshti, Jeffrey C. Lee, Katsuhiko Naoki, William G. Richards et al. · 2005 · Cancer Research
  40. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
    Miguel Tarón, Yukito Ichinose, Rafael Rosell, Tony S.K. Mok, Bartomeu Massutí, Lurdes Zamora, José Luís Mate, Christian Manegold, Mayumi Ono, Cristina Queralt et al. · 2005 · Clinical Cancer Research
  41. Focal adhesion signaling and therapy resistance in cancer
    Iris Eke, Nils Cordes · 2014 · Seminars in Cancer Biology
  42. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells
    Faye M. Johnson, Babita Saigal, Moshe Talpaz, Nicholas J. Donato · 2005 · Clinical Cancer Research
  43. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
    David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Idharan Gururangan, James J. Vredenburgh, Annick Desjardins, Sith Sathornsumetee, James M. Provenzale, James E. Herndon et al. · 2005 · Journal of Clinical Oncology
  44. COSMIC 2005
    Simon Andrew Forbes, Jody Clements, Elisabeth Dawson, Sally Bamford, Tony Webb, Ahmet Doǧan, Adrienne Margaret Flanagan, Jon W. Teague, Richard Wooster, P. Andrew Futreal et al. · 2006 · British Journal of Cancer
  45. Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
    Tsuyoshi Takahashi, Makoto Sonobe, Masashi Kobayashi, Akihiko Yoshizawa, Toshi Menju, Ei Nakayama, Nobuya Mino, Shotaro Iwakiri, Kiyoshi Sato, Ryo Miyahara et al. · 2009 · Annals of Surgical Oncology
  46. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
    Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I. et al. · 2014 · Annals of Oncology
  47. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
    Richard M Simon, Aboubakar Maitournam · 2004 · Clinical Cancer Research
  48. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
    Katsuya Nakai, Mien‐Chie Hung, Hirohito Yamaguchi · 2016 · Europe PMC (PubMed Central)
  49. Illuminating the dark phosphoproteome
    Elise J. Needham, Benjamin L. Parker, Timur Burykin, David Ernest James, Sean J. Humphrey · 2019 · Science Signaling
  50. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
    Yixuan Gong, Romel Somwar, Katerina A. Politi, Marissa N. Balak, Juliann Chmielecki, Xuejun Jiang, William J. Pao · 2007 · PLoS Medicine
  51. Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
    Bart A. Lutterbach, Qinwen Zeng, Lenora J. Davis, Harold Hatch, Gaozhen Hang, Nancy E. Kohl, W. Wayt Gibbs, Bo‐Sheng Pan · 2007 · Cancer Research
  52. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
    Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, Hideo Kunitoh, Tomohide Tamura, Brian R. Holloway, Kazuto Nishio · 2006 · Clinical Cancer Research
  53. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
    Recondo, Gonzalo, Facchinetti, Francesco, Olaussen, Ken A., Besse, Benjamin, Friboulet, Luc · 2018 · Nature Reviews Clinical Oncology
  54. Pharmacogenomics: bench to bedside
    Richard M. Weinshilboum, Liewei Wang · 2004 · Nature Reviews Drug Discovery
  55. Refining the treatment of NSCLC according to histological and molecular subtypes
    Anish Thomas, Stephen V. Liu, Deepa Suresh Subramaniam, Giuseppe Giaccone · 2015 · Nature Reviews Clinical Oncology
  56. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
    Wu, Jenn-Yu, Wu, Shang-Gin, Yang, Chih-Hsin, Gow, Chien-Hung, Chang, Yih-Leong, Yu, Chong-Jen, Shih, Jin-Yuan, Yang, Pan-Chyr · 2008 · Clinical Cancer Research
  57. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
    Federico Cappuzzo, Pasi Antero Janne, Margaret C. Skokan, Giovanna Finocchiaro, Elisa Rossi, C. Ligorio, Paolo Andrea Zucali, Luigi Terracciano, Luca Toschi, Massimo G. Roncalli et al. · 2008 · Annals of Oncology
  58. EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
    Leora Horn, William J. Pao · 2009 · Journal of Clinical Oncology
  59. Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation
    Porta, R., Sánchez-Torres, J.M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P. et al. · 2011 · European Respiratory Journal
  60. Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
    Taniguchi, Kazuya, Uchida, Junji, Nishino, Kazumi, Kumagai, Toru, Okuyama, Takako, Okami, Jiro, Higashiyama, Masahiko, Kodama, Ken, Imamura, Fumio, Kato, Kikuya · 2011 · Clinical Cancer Research
  61. Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
    Deepali Sachdev, Douglas Yee · 2008 · AACR Education book
  62. The EMT regulator slug and lung carcinogenesis
    Jin-Yuan Shih, Pan‐Chyr Yang · 2011 · Carcinogenesis
  63. Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
    Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li, Chun-Yen Hsiao, Chin‐Yuan Tzen, Kuo-Ting Chang, Yuh‐Min Chen, Reury-Perng Perng, Shih‐Feng Tsai, Chun‐Ming Tsai · 2005 · Clinical Cancer Research
  64. Somatic Mutations ofEGFRin Colorectal Cancers and Glioblastomas
    Thomas D. Barber, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu · 2004 · New England Journal of Medicine
  65. Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging
    Aaron M. Rutman, Michael Kuo · 2009 · European Journal of Radiology
  66. Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
    Toru Mukohara, Jeffrey A. Engelman, Nasser H. Hanna, Beow Yong Yeap, Susumu S. Kobayashi, Neal Ian Lindeman, Balázs Halmos, Joseph Pearlberg, Zenta Tsuchihashi, Lewis C. Cantley et al. · 2005 · JNCI Journal of the National Cancer Institute
  67. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies
    Lena Gorgannezhad, Muhammad Umer, Md. Nazmul Islam, Nam‐Trung Nguyen, Muhammad J. A. Shiddiky · 2018 · Lab on a Chip
  68. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas
    Ying Liu, Jongphil Kim, Yoganand Balagurunathan, Qian Li, Alberto López García, Olya Stringfield, Zhaoxiang Ye, Robert J. Gillies · 2016 · Clinical Lung Cancer
  69. High frequency of BRAF V600E mutations in ameloblastoma
    Kari J. Kurppa, Javier Catón, Peter R. Morgan, Ari P. Ristimaki, B. Ruhin, Jari K. Kellokoski, Klaus Elenius, Kristiina Heikinheimo · 2013 · The Journal of Pathology
  70. Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
    Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Augusto Villanueva, Beatriz Mínguez, Josep Maria Llovet · 2010 · Seminars in Liver Disease
  71. Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
    Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, Heinrich Röder, Robert J. Gray, Kazuo Kasahara, Makoto Nishio, Julie Renee Brahmer, Anna Spreafico, Vienna Ludovini et al. · 2007 · JNCI Journal of the National Cancer Institute
  72. Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices
    Nathan A. Pennell, Maria E. Arcila, David R. Gandara, Howard West · 2019 · American Society of Clinical Oncology Educational Book
  73. Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
    Jura, Natalia, Zhang, Xuewu, Endres, Nicholas F., Seeliger, Markus A., Schindler, Thomas, Kuriyan, John · 2011 · Molecular Cell
  74. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
    Erin Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming‐Sound Tsao · 2015 · Europe PMC (PubMed Central)
  75. Self-Assembly Synthesis, Tumor Cell Targeting, and Photothermal Capabilities of Antibody-Coated Indocyanine Green Nanocapsules
    Jie Zhong Yu, David J. Javier, Mohammad Abbas Yaseen, Nitin Nitin, Rebecca Rae Richards-Kortum, Bahman Anvari, Michael S. Wong · 2010 · Journal of the American Chemical Society
  76. Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
    Amit Kumar, Edward T. Petri, Balázs Halmos, Titus J. Boggon · 2008 · Journal of Clinical Oncology
  77. Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
    Bryan C. Fuchs, Tsutomu Fujii, Jon D. Dorfman, Jonathan M. Goodwin, Andrew Xiuxuan Zhu, Michael D. Lanuti, Kenneth K. Tanabe · 2008 · Cancer Research
  78. Recent Advances in the Treatment of Malignant Astrocytoma
    David A. Reardon, Jeremy N. Rich, Henry S. Friedman, Darell D. Bigner · 2006 · Journal of Clinical Oncology
  79. Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts
    David Neil Hayes, Stefano Monti, Giovanni Parmigiani, C. Blake Gilks, Katsuhiko Naoki, Arindam Bhattacharjee, Mark A. Socinski, Charles M. Perou, Matthew M. Meyerson · 2006 · Journal of Clinical Oncology
  80. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects
    Laura P. Stabile, Jennifer S. Lyker, Christopher T. Gubish, Weiping Zhang, Jennifer Rubin Grandis, Jill M. Siegfried · 2005 · Cancer Research
  81. Flying under the radar: the new wave of BCR–ABL inhibitors
    Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jörge E. Cortes · 2007 · Nature Reviews Drug Discovery
  82. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
    Michael R. Burgess, Brian J. Skaggs, Neil P. Shah, Francis Y. Lee, Charles L. Sawyers · 2005 · Proceedings of the National Academy of Sciences
  83. Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
    David Michael Jackman, Beow Yong Yeap, Neal Ian Lindeman, Panos Fidias, Michael S. Rabin, Jennifer S. Temel, Arthur T. Skarin, Matthew M. Meyerson, Alison Holmes Tisch, Ana M. Borras et al. · 2007 · Journal of Clinical Oncology
  84. A comprehensive review of protein kinase inhibitors for cancer therapy
    Radhamani Kannaiyan, Daruka Mahadevan · 2018 · Expert Review of Anticancer Therapy
  85. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
    Pasi Antero Janne, Nathanael S. Gray, Jeff Settleman · 2009 · Nature Reviews Drug Discovery
  86. Mechanisms for oncogenic activation of the epidermal growth factor receptor
    Roza Zandi, Alice Bjerregaard Larsen, Peter Andersen, Marie‐Thérése Stockhausen, Hans Skovgaard Poulsen · 2007 · Cellular Signalling
  87. HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
    Kavuri, Shyam M., Jain, Naveen, Galimi, Francesco, Cottino, Francesca, Leto, Simonetta M., Migliardi, Giorgia, Searleman, Adam C., Shen, Wei, Monsey, John, Trusolino, Livio et al. · 2015 · Cancer Discovery
  88. Integration of EGFR inhibitors with radiochemotherapy
    Mukesh Kumar Nyati, Meredith Ann Morgan, Felix Yi-Chung Feng, Theodore Steven Lawrence · 2006 · Nature reviews. Cancer
  89. <i>EGFR</i> mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
    Ellison, Gillian, Zhu, Guanshan, Moulis, Alexandros, Dearden, Simon, Speake, Georgina, McCormack, Rose · 2013 · Journal of Clinical Pathology
  90. Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
    Sandra P. D’Angelo, Maria Catherine Pietanza, Melissa Lynne Johnson, Gregory J. Riely, Vincent A. Miller, Camelia S. Sima, Maureen Frances Zakowski, Valerie W. Rusch, Marc Ladanyi, Mark G. Kris · 2011 · Journal of Clinical Oncology
  91. Mouse models for human lung cancer
    Ralph Leo Johan Meuwissen, Anton J. M. Berns · 2005 · Genes & Development
  92. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
    David A. Eberhard, Giuseppe Giaccone, Bruce Evan Johnson · 2008 · Journal of Clinical Oncology
  93. Translating insights from the cancer genome into clinical practice
    Lynda Chin, Joe W. Gray · 2008 · Nature
  94. RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
    Qing‐Bai She, Sarat Chandarlapaty, Qing Ye, Jose M. Lobo, Kathleen Haskell, Karen R. Leander, Deborah Defeo-Jones, Hans E. Huber, Neal X. Rosen · 2008 · PLoS ONE · Retracted
  95. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
    Mitsuhiko Hanawa, Shioto Suzuki, Yoh Dobashi, Tetsu Yamane, Koji Kono, Nobuyuki Enomoto, Akishi Ooi · 2005 · International Journal of Cancer
  96. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
    Yi-Long Lung Cancer Wu, Jin Soo Lee, Sumitra Thongprasert, Chong‐Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu et al. · 2013 · The Lancet Oncology
  97. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Wang, Wei, Li, Qi, Yamada, Tadaaki, Matsumoto, Kunio, Matsumoto, Isao, Oda, Makoto, Watanabe, Go, Kayano, Yoshiyuki, Nishioka, Yasuhiko, Sone, Saburo et al. · 2009 · Clinical Cancer Research
  98. Receptor Tyrosine Kinase-Targeted Cancer Therapy
    Yamaoka, Toshimitsu, Kusumoto, Sojiro, Ando, Koichi, Ohba, Motoi, Ohmori, Tohru · 2018 · International Journal of Molecular Sciences
  99. A Translational View of the Molecular Pathogenesis of Lung Cancer
    Mitsuo Sato, David S. Shames, Adi F. Gazdar, John Dorrance Minna · 2007 · Journal of Thoracic Oncology
  100. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
    Vincent A. Miller, Gregory J. Riely, Maureen Frances Zakowski, Allan R. Li, Jyoti D. Patel, Robert T. Heelan, Mark G. Kris, Alan B. Sandler, David Paul Carbone, Anne S. Tsao et al. · 2008 · Journal of Clinical Oncology